EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
+6.51%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.95B
AUM Growth
+$137M
(+7.6%)
Cap. Flow
+$70.7M
Cap. Flow
% of AUM
3.63%
Top 10 Holdings %
Top 10 Hldgs %
62.7%
Holding
375
New
57
Increased
197
Reduced
86
Closed
22
Top Buys
| 1 |
Apple
AAPL
|
$12.2M |
| 2 |
Microsoft
MSFT
|
$12.2M |
| 3 |
NVIDIA
NVDA
|
$9.41M |
| 4 |
Broadcom
AVGO
|
$6.49M |
| 5 |
Pinduoduo
PDD
|
$5.98M |
Top Sells
| 1 |
ASE Group
ASX
|
$18.3M |
| 2 |
Sea Limited
SE
|
$11.3M |
| 3 |
TSMC
TSM
|
$9.44M |
| 4 |
ZTO Express
ZTO
|
$7.08M |
| 5 |
NIO
NIO
|
$4.53M |
Sector Composition
| 1 | Consumer Discretionary | 37.74% |
| 2 | Technology | 30.94% |
| 3 | Communication Services | 8.5% |
| 4 | Healthcare | 6.31% |
| 5 | Financials | 5.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
GlobalFoundries
GFS
$18.5B
| $207K | 0.01% |
5,146
+431
| +9% | +$17.3K |
|
327
Insulet
PODD
$24.5B
| $207K | 0.01% |
+888
| New | +$207K |
|
328
Apogee Therapeutics
APGE
$2.26B
| $206K | 0.01% |
+3,506
| New | +$206K |
|
329
Molina Healthcare
MOH
$9.47B
| $206K | 0.01% |
+597
| New | +$206K |
|
330
Henry Schein
HSIC
$8.42B
| $203K | 0.01% |
+2,789
| New | +$203K |
|
331
Viatris
VTRS
$12.2B
| $202K | 0.01% |
17,426
-1,336
| -7% | -$15.5K |
|
332
Universal Health Services
UHS
$12.1B
| $202K | 0.01% |
+880
| New | +$202K |
|
333
Teleflex
TFX
$5.78B
| $201K | 0.01% |
+813
| New | +$201K |
|
|
CTLT
334
DELISTED
CATALENT, INC.
CTLT
| $201K | 0.01% |
+3,319
| New | +$201K |
|
335
Dynavax Technologies
DVAX
$1.18B
| $188K | 0.01% |
16,856
-2,073
| -11% | -$23.1K |
|
336
BioCryst Pharmaceuticals
BCRX
$1.74B
| $181K | 0.01% |
23,838
-4,447
| -16% | -$33.8K |
|
337
Arcutis Biotherapeutics
ARQT
$2.06B
| $165K | 0.01% |
17,785
+2,026
| +13% | +$18.8K |
|
338
MannKind Corp
MNKD
$1.7B
| $127K | 0.01% |
20,211
-1,068
| -5% | -$6.72K |
|
339
ImmunityBio
IBRX
$2.27B
| $109K | 0.01% |
29,278
+2,820
| +11% | +$10.5K |
|
340
Ironwood Pharmaceuticals
IRWD
$188M
| $105K | 0.01% |
25,485
+2,143
| +9% | +$8.83K |
|
341
Applied Therapeutics
APLT
$68.2M
| $87K | ﹤0.01% |
+10,232
| New | +$87K |
|
342
Humacyte
HUMA
$226M
| $86.3K | ﹤0.01% |
+15,869
| New | +$86.3K |
|
343
Sana Biotechnology
SANA
$752M
| $85.7K | ﹤0.01% |
20,590
-85
| -0.4% | -$354 |
|
344
Vir Biotechnology
VIR
$732M
| $83.7K | ﹤0.01% |
+11,170
| New | +$83.7K |
|
345
Relay Therapeutics
RLAY
$710M
| $81.8K | ﹤0.01% |
11,550
-228
| -2% | -$1.61K |
|
346
Annexon
ANNX
$238M
| $67.3K | ﹤0.01% |
+11,361
| New | +$67.3K |
|
|
VERV
347
DELISTED
Verve Therapeutics
VERV
| $65.6K | ﹤0.01% |
+13,554
| New | +$65.6K |
|
348
Altimmune
ALT
$334M
| $61.5K | ﹤0.01% |
10,010
-3,448
| -26% | -$21.2K |
|
349
Allogene Therapeutics
ALLO
$255M
| $57K | ﹤0.01% |
20,363
-4,970
| -20% | -$13.9K |
|
350
Ocugen
OCGN
$322M
| $50.8K | ﹤0.01% |
51,227
+2,815
| +6% | +$2.79K |
|